EculizumabLow-middle income countriesJournal of Nephrology - Atypical hemolytic uremic syndrome (aHUS) is an ultra-rare disease and eculizumab was approved as first line therapy in 2011 by the Food and Drug Administration. Access to...doi:10.1007/s40620-022-01282-4Nga, Hong Si...
Epysqli(eculizumab-aagh), a biosimilar to Soliris Ahzantive(aflibercept-mrbb), a biosimilar to Eylea Nypozi(filgrastim-txid), a biosimilar to Neupogen Pyzchiva(ustekinumab-ttwe), an biosimilar to Stelara Bkemv(eculizumab-aeeb), designated as an interchangeable biosimilar to Soliris Yesafili(aflibe...
(orthodontic) braces for children, medicines for patients with Alzheimer’s disease, for patients with heartburn (pyrosis), and for children with Attention Deficit Hyperactivity Disorder, the orphan drug eculizumab for patients with atypical Hemolytic Uremic Syndrome (aHUS), a total body scan, ...
Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial Blood Adv, 2 (19) (2018), pp. 2543-2549 View PDFView articleCrossrefView in ScopusGoogle Scholar 27 E Ulvestad Paradoxical haemolysis in a patient with cold agglutinin disease Eu...
Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity Clin Case Rep, 3 (11) (2015), pp. 942-944 CrossrefGoogle Scholar 78 A Gueli, D Gottardi, H Hu, I Ricca, A De Crescenzo, C Tarella Efficacy of rituximab-bendamustine in cold ag...
Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity Clin Case Rep, 3 (11) (2015), pp. 942-944 CrossrefGoogle Scholar 78 A Gueli, D Gottardi, H Hu, I Ricca, A De Crescenzo, C Tarella Efficacy of rituximab-bendamustine in cold ag...